MaaT Pharma (EPA:MAAT) CHMP rejection shifts attention to September appeal, cash runway
MaaT Pharma shares fell 3.9% to 2.60 euros after the EMA’s CHMP issued a negative opinion on Xervyteg, its lead therapy, citing concerns over data attribution; MaaT will seek a re-examination before a September review, with its cash runway extending only to November 2026.